July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
Validation of the use of a circulating biomarker of retinal omega-3 polyunsaturated fatty acids in supplementation conditions: the BLISAR project
Author Affiliations & Notes
  • Lionel Bretillon
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
  • Benedicte MJ Merle
    Inserm U1219- Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
  • Lucy Martine
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
  • Stephane Gregoire
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
  • Soufiane Ajana
    Inserm U1219- Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
  • Olivier Berdeaux
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
  • Alain M Bron
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
    Department of Ophthalmology, University Hospital, Dijon, France
  • Catherine Creuzot-Garcher
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
    Department of Ophthalmology, University Hospital, Dijon, France
  • Jean-Francois Korobelnik
    Inserm U1219- Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
    Department of Ophthalmology, University Hospital, Bordeaux, France
  • Niyazi Acar
    UMR CSGA – Eye and Nutrition Research Group, INRA, Dijon, France
  • Cecile DelCourt
    Inserm U1219- Bordeaux Population Health Research Center, University of Bordeaux, Bordeaux, France
  • Footnotes
    Commercial Relationships   Lionel Bretillon, Horus (R); Benedicte Merle, Bausch&Lomb (R), Thea (R); Lucy Martine, None; Stephane Gregoire, None; Soufiane Ajana, None; Olivier Berdeaux, None; Alain Bron, Aerie, Allergan (C), Bausch Lomb (C), Santen (C), Théa (C); Catherine Creuzot-Garcher, Allergan, Bayer, Bausch and Lomb (C), Horus (C), Novartis (C), Roche (C), Théa (C); Jean-Francois Korobelnik, Allergan (C), Baush&Lomb (C), Bayer (C), Beaver Visitec (C), Horus (C), Kanghong (C), Krys (C), NanoRetina (C), Novartis (C), Roche (C), Thea (C), Zeiss (C); Niyazi Acar, Bausch&Lomb (R); Cecile DelCourt, Allergan (C), Bausch&Lomb (C), Novartis (C), Roche (C), Théa (C)
  • Footnotes
    Support  Agence Nationale de la Recherche [ANR-14-CE12-0020-01 BLISAR; ANR11-LABX-0021-01]; Conseil Régional Bourgogne, Franche-Comté [PARI grant]; FEDER (European Funding for Regional Economical Development); Fondation de France/Fondation de l'oeil; Laboratoires Théa
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 1170. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Lionel Bretillon, Benedicte MJ Merle, Lucy Martine, Stephane Gregoire, Soufiane Ajana, Olivier Berdeaux, Alain M Bron, Catherine Creuzot-Garcher, Jean-Francois Korobelnik, Niyazi Acar, Cecile DelCourt; Validation of the use of a circulating biomarker of retinal omega-3 polyunsaturated fatty acids in supplementation conditions: the BLISAR project. Invest. Ophthalmol. Vis. Sci. 2019;60(9):1170. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : In the context of the Biomarkers of LIpid Status And Metabolism in Retinal ageing (BLISAR) project, we have identified a blood biomarker of the retinal content in omega-3 PUFAS that is discriminant for AMD. The aim of this study was to evaluate the levels of this biomarker in human subjects supplemented with omega-3 PUFAs.

Methods : The analyses were performed on samples issued from 55 subjects that participated to the LIMPIA randomized clinical trial (Korobelnik et al JAMA Ophthalmol. 2017;135(11):1259-1266). Briefly, healthy subjects aged of 56.7 ± 6.6 years were supplemented for 6 months with supplements containing either 676mg of omega-3 PUFAs or a placebo. Blood samples were collected at baseline and after 3 and 6 months of supplementation. Plasma cholesteryl esters were isolated from total plasma by thin-layer chromatography (TLC) and their fatty acid composition was determined by gas chromatography coupled to flame ionization detection (GC-FID). The predictor levels were calculated according to the algorithm previously developed in the BLISAR project and association with supplementation status was assessed.

Results : At baseline, the predicted levels of retinal omega-3 PUFA concentrations were of 19.0±2.3% and 18.4±1.3% (percentage of total fatty acids) in placebo and supplemented groups respectively (p=0.25). After 3 months of supplementation, a significant increase in predicted levels of retinal omega-3 PUFAs was observed in the supplemented group (21.7±2.0% versus 18.8±1.9% in supplemented and placebo groups, respectively p<0.0001). This difference was maintained after 6 months of supplementation (21.9±2.5% versus 19.0±2.3% in supplemented and placebo groups, respectively p<0.0001).

Conclusions : The data show that a 3-month supplementation with 676mg of omega-3 PUFAs is sufficient to reach a plateau in the predicted levels of retinal omega-3 PUFAs. In addition to giving information on the predicted kinetics of incorporation of omega-3 PUFAs into the retina, these data illustrate the usefulness of such a biomarker in supplementation trials in order to follow both the compliance to the treatment and the efficacy of the supplementation.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×